Relative to routine stenting, drug-eluting balloon revascularization with as-needed stenting produced similarly low target ...

The data were presented by Principal Investigator Prof. Ulf Teichgräber during a podium first session on '3-year results from ...

For the first time, a product is available specifically for use in patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors. The product is an ...

The two medications can be administered concomitantly if various factors are taken into account. CHICAGO—Clinicians can safely use sirolimus and voriconazole concurrently if certain steps are followed ...

The subanalysis aligns with the main trial findings, suggesting no difference in TVF at 1 year compared with DES.

T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous ...

Please provide your email address to receive an email when new articles are posted on . Four of six patients who used sirolimus had positive responses and discontinued systemic corticosteroids. Three ...

Graft-vs-host disease (GVHD) remains the most significant cause of morbidity and mortality after allogeneic stem cell transplantation. Despite this, the combination of a calcineurin inhibitor with ...

The patients began treatment with oral sirolimus; after 1 year of treatment, there was improvement in exertional dyspnea in all 3 patients. HealthDay News — Sirolimus may be beneficial for patients ...

Acute GVHD (aGVHD) is a major cause of morbidity and mortality in hematopoietic allograft recipients. The best therapy for patients failing to respond, or not tolerating, systemic glucocorticoids ...

Newark, May 22, 2024 (GLOBE NEWSWIRE) -- The Brainy Insights estimates that the USD 250 million in 2023 global sirolimus market will reach USD 370.06 million in 2033. Sirolimus is also known as ...